slide1
Download
Skip this Video
Download Presentation
Adjuvant Endometrial Cancer Trial [email protected]

Loading in 2 Seconds...

play fullscreen
1 / 2

Adjuvant Endometrial Cancer Trial [email protected] - PowerPoint PPT Presentation


  • 201 Views
  • Uploaded on

Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer: Does proper lymphadenectomy improve survival? LYTEC Trial & AGO-ECLAT trial Is there a need for adjuvant chemotherapy in node negative high-risk early stage patients?

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Adjuvant Endometrial Cancer Trial [email protected]' - elise


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer:

  • Does proper lymphadenectomy improve survival?
    • LYTEC Trial & AGO-ECLAT trial
  • Is there a need for adjuvant chemotherapy in node negative
  • high-risk early stage patients?
    • ENGOT-EN2-DGCG trial
  • Is adjuvant chemo followed by RT better than chemo alone
  • in high-risk nodal status unknown early stage or stage 3 patients?
    • NSGO trial
  • Can combination of standard chemotherapy with targeted therapy compared to combination chemotherapy alone improve disease control rate of advanced or chemo-naïve relapsed endometrial cancer? AGO/NOGGO trial

Adjuvant Endometrial Cancer Trial [email protected]

slide2

ENGOT-NESTEC:NEtwork STudy in Endometrial Cancer

under the ENGOT umbrella and in cooperation with the Mayo clinic.

Clinically presumed: FIGO IB-II any histo type, FIGO I A G3 endometroid, FIGO IA/B histo type II

Mayo trial (Dowdy, Mariani)

AGO ECLAT trial (Emons)

R

R

NSGO trial (Hogberg)

surgery

R

AGO/NOGGO trial (Sehouli)

R

DGCG trial (Mirza)

No bulky LN

Bulky LN

FIGO III not Ro and pos. LN or cytology only; FIGO IV

Recurrent FIGO I/II

In OP

LNE

R

N-

N+

+ extra LN disease

R

LNE*

no LNE

without extra LN disease

N-

N+

Standard arm:

Carbo-paclitaxel

+ Placebo

Experim. arm:

Carbo-paclitaxel

+ mTOR inhibitor

R

Chemo 1

Carbo-paclitaxel

R

Chemo +.

Radiotherapy

Chemo 1

Carbo-paclitaxel

observation

ad